医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Genor Biopharma, a Pre-commercial Stage Biopharma Company, Announced the Appointment of Jack Hu as Chief Financial Officer and Chief Strategy Officer

2019年09月03日 PM08:04
このエントリーをはてなブックマークに追加


 

SHANGHAI

Before joining Genor, Dr. Hu served as Managing Director and Head of APAC Healthcare Research at Deutsche Bank, where he covered Asia/China healthcare. Dr. Hu joined Deutsche Bank in 2010 and was ranked No.1 for All-China healthcare research by Institutional Investor magazine from 2015 to 2017. As a seasoned healthcare professional with deep knowledge of the biotech sector, Dr. Hu has nearly 20 years of experience working in equity research, hedge funds and multinational biopharmaceutical companies. Dr. Hu received a Ph.D. in molecular genetics from the M.D. Anderson Cancer Center and began his career at Wyeth (now part of Pfizer). He also covered the US biotech sector as a senior biotech analyst with Oppenheimer.

“I believe Dr. Hu’s extensive expertise will help Genor realize its vision of offering innovative, best-in class therapies to serve unmet patient needs. Dr. Hu’s deep knowledge of the healthcare industry and expertise in the financial and capital markets make him a vital addition to Genor’s talented leadership,” said Michael Xu, CEO of Genor, “Dr. Hu joins us at an important inflection point as our business becomes more global. We are excited to work with Dr. Hu in continuing to build strong corporate partnerships and our strategic financial capabilities,” added Mr. Xu.

“I am excited to join Genor, a firm that is committed to bringing life changing therapeutics to patients. I look forward to working with this dynamic team to create value for shareholders.” Dr. Hu commented.

About Genor Biopharma

Genor Biopharma is a clinical-stage biopharmaceutical company located in Zhangjiang, Shanghai, China. Genor is focused on the therapeutic areas of oncology and autoimmune diseases. The Company delivers a portfolio of novel therapies built to address unmet medical needs. The Company’s leading product candidates are late stage innovative monoclonal antibodies. Genor maintains state-of-the-art manufacturing facilities with cGMP capabilities in both Shanghai and Yunnan.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005452/en/

CONTACT

Press:

Lily Zhu

Lily.zhu@genorbio.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH
  • 拓臻生物公布其非酒精性脂肪性肝炎(NASH)候选药物-具有肝脏选择性的法尼醇X受体(FXR)激动剂TERN-101-临床Ⅰ期试验安全性和药效学研究结果
  • AVITA Medical Half-Year Financial Report for Fiscal 2020
  • 西联汇款启动抗击新型冠状病毒的全球援助项目
  • Jinsan Beverage of Korea Introduces Its 5 Healthy Smoothies for Spring